Patient death in Sophiris' prostate cancer trial deemed unrelated to topsalysin

Sophiris Bio Inc. (NASDAQ:SPHS) said that the patient death reported in June from a Phase IIb trial evaluating topsalysin (PRX302)

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE